Analyst firms · Leerink Partners · ILMN
Leerink Partners ILMN price target and rating history
Illumina Inc. (ILMN) · Health Care
Leerink Partners rates Illumina Inc. (ILMN) Outperform with a $270 price target, as of its latest action on Oct 4, 2022. It has published 5 rating actions on ILMN since August 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.
- Current rating
- Outperform
- Price target
- $270
- Median target, all firms
- $185
- Actions on ILMN
- 5
Leerink Partners price target on ILMN
Every Leerink Partners rating on ILMN
- Oct 4, 2022
- Feb 11, 2022
- Jan 11, 2022
- Oct 19, 2021
- Aug 19, 2021
How other firms rate ILMN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Stephens | Equal-Weight | $275 | Oct 23, 2026 |
| UBS | Buy | $260 | Sep 9, 2026 |
| Bernstein | Mkt Perform | $185 | Jun 26, 2026 |
| RBC Capital Markets | Outperform | $170 | May 15, 2026 |
| Daiwa | Outperform | $155 | May 14, 2026 |
Questions about Leerink Partners and ILMN
- What is Leerink Partners's price target for ILMN?
- Leerink Partners's latest stated price target for Illumina Inc. (ILMN) is $270, from its action on Oct 4, 2022.
- What is Leerink Partners's rating on ILMN?
- Leerink Partners rates ILMN Outperform, a bullish rating, as of Oct 4, 2022.
- When did Leerink Partners last change its view on ILMN?
- On Oct 4, 2022, Leerink Partners upgrades to Outperform from Mkt Perform, price target $220 to $270.
- How does Leerink Partners's ILMN target compare with other analysts?
- Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.
More ILMN rating histories
All Leerink Partners ratingsILMN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.